Annual Report Searches
Alphabetical Search

Advertisers


LEXICON PHARMACEUTICALS INC (LXRX:NASDAQ)

Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science, based on Nobel Prize-winning technology, to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000 program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in oncology, diabetes and metabolism.


Yearly Figures
(in thousands, except per share amounts)
FYE: 12/31 2015 2014 2013 2012
Net Revenues $130,014 $22,854 $2,222 $1,089
Net Income (Loss) ($4,682) ($100,294) ($104,126) ($110,211)
Earnings Per Share (0.05) (1.31) (1.4) (1.61)
Quarterly Figures
(in thousands, except per share amounts)
              Third Quarter
FYE: 12/31 9/30/16 9/30/15
Net Revenues $27,717 $566
Net Income (Loss) ($36,015) ($35,282)
Earnings Per Share (0.35) (0.34)
Contact Information
Contact Name: Alex Abuin
Contact Title: Vice President, Corporate Communications
Phone: 1-281-863-3000